ALGOTHERAPEUTIX
15.12.2020 08:17:14 CET | Business Wire | Press release
France-based biotechnology company AlgoTherapeutix, the developer of an innovative topical treatment for chemotherapy-induced peripheral neuropathy (CIPN), announced today it has received approval from the ethics committee and the regulatory authority in the Czech Republic to initiate a Phase 1 clinical trial with ATX01. The trial, which will explore the pharmacokinetics and safety of ATX01 in healthy volunteers, is due to start in January 2021.
AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinical development of ATX01. Given a positive outcome of the approved Phase 1 study, the company intends to initiate Phase 2 by the end of 2021.
Stéphane Thiroloix , Founder & CEO of AlgoTherapeutix, says: “I am thrilled by the entry of ATX01 in clinical development as it represents a great step forward towards providing CIPN patients with a response to the crippling pain they endure.”
Over half of cancer patients treated with chemotherapy - over two million patients in the US and Europe - develop CIPN and experience sensory symptoms and pain in the hands and feet: loss of sensitivity, tingling, burning, cold and intense pain can persist for months to years after treatment. CIPN is a leading cause for modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists and pain specialists.
Over the last two years, AlgoTherapeutix took ATX01 from exploratory prototype to final formulation, established its pharmacological profile, conducted a full pre-clinical toxicology package, and scaled-up manufacturing to enable clinical supply production. In parallel, AlgoTx firmed-up ATX01’s development pathway via a pre-IND consultation with the FDA and obtained an Orphan Drug Designation from the FDA to explore ATX01’s activity in erythromelalgia.
A recent publication in the “Journal of Pain” describes the exploratory pharmacological impact of high-dose topical amitriptyline in CIPN patients along with the mechanism of action supporting its activity (https://doi.org/10.1016/j.jpain.2020.11.002 )
About AlgoTherapeutix
AlgoTx was founded in 2018 by Stéphane Thiroloix and Olivier Bohuon to develop topical treatments for complex pain and was incubated by Paris Biotech Santé. Their lead programme ATX01 is in clinical development in Chemotherapy-Induced Peripheral Neuropathy. More information at www.algotx.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005352/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wolters Kluwer Releases 2026 Future Ready Lawyer Survey Report, Highlighting Rapid AI Gains and Shifting Power Dynamics10.3.2026 13:00:00 CET | Press release
Global survey of legal professionals reveals strong momentum behind AI investment and workflow transformation Wolters Kluwer Legal & Regulatory has published the results of its global 2026 Future Ready Lawyer Survey, the preeminent source of insights from lawyers in law firms and corporate legal departments across the U.S., China and nine European countries. The findings show an industry coming to grips with the accelerated adoption of AI technology, an ambitious undertaking that has yielded long sought-after efficiencies across workflows and business practices, while raising unexpected challenges to ethics and infrastructure. “The Future Ready Lawyer global report has always reflected an industry in motion,” said Martin O'Malley, CEO of Wolters Kluwer Legal & Regulatory. “What’s most striking this year is how rapidly legal professionals are accelerating to meet that change by reshaping business models, rethinking long‑held dynamics, and embracing new ways to deliver value through both
Armis Announces Armis Centrix™ for Vulnerability Management Detection and Response to Reduce Cyber Risk and Eliminate Operational Friction10.3.2026 13:00:00 CET | Press release
Solution empowers organizations to continuously and accurately detect vulnerabilities across the entire attack surface, while reducing scan volume and impact Armis, the cyber exposure management & security company, today announced Armis Centrix™ for Vulnerability Management Detection and Response. The solution enables security teams to precisely identify and validate vulnerabilities across all of an organization’s assets in real time. Armis’ unified approach to vulnerability assessment results in greater accuracy, faster detection time and reduced operational costs. "Waiting weeks for a vulnerability scan that still misses essential assets is no longer sufficient to combat AI-powered cyberattacks,” said Nadir Izrael, CTO and Co-Founder at Armis. “Organizations need a continuous view of their complete environment to stay ahead of threats. Armis' new solution delivers more accurate, targeted results than traditional vulnerability management solutions with a fraction of the scans. It empo
United UATP, Powered by TreviPay, Expands Corporate Travel Billing Program to New Global Markets10.3.2026 13:00:00 CET | Press release
Strategic market entry to Europe, Australia and New Zealand further strengthens United Airlines’ ability to serve agency and corporate customers with cost-free billing, flexible air travel payment options and enhanced reporting tools UATP, the global network that enables organizations to simplify payment processes and expand their payment capabilities, today announced the expansion of United Airlines’ cost-free UATP billing program (“United UATP”), powered by TreviPay, to Europe, Australia and New Zealand. This expansion opens new opportunities for corporate customers and travel agencies in these regions to access the benefits of United UATP, including cost-free, streamlined travel expense reconciliation. Since 2015, United UATP has collaborated with TreviPay, a fully managed B2B payments platform, to power its streamlined solution for air travel payments in the U.S. and Canada. For companies currently benefitting from the United UATP billing program, TreviPay handles customer service,
Nexpring Health Invests in May Health to Advance a Novel Technology to Treat PCOS-Related Infertility10.3.2026 13:00:00 CET | Press release
Strategic investment advances Nexpring Health's mission to move the fertility field forward, placing clinicians, embryologists, and fertility clinics at the center of every breakthrough, so they can focus on what matters most, their patients. Nexpring Health, a global leader in assisted reproductive technology (ART) solutions, today announced a strategic investment in May Health, a medical device company pioneering a novel treatment approach for women with polycystic ovary syndrome (PCOS)-related infertility. Nexpring Health joined May Health’s €10 million ($11.7M) financing round alongside investors including Sofinnova Partners, Trill Impact, and Bpifrance. This investment reflects Nexpring Health's commitment to driving meaningful innovation that moves the field of fertility care forward and goes beyond the products in the lab by supporting the innovations that redefine what’s possible for patients and the clinicians who serve them. Backing the Breakthrough That PCOS Patients Need PC
Perion's AI Agent Outmax Now Available for TikTok, Delivering Up to 25% Greater Media Performance in Early Results10.3.2026 12:00:00 CET | Press release
Perion's extension into one of the fastest-growing advertising platforms represents a big leap in TAM expansion, as TikTok Ad Revenue is expected to exceed $50 billion by 2027 Perion Network Ltd. (NASDAQ and TASE: PERI), an advanced technology leader solving for the complexities of digital advertising through AI-native execution infrastructure, today announced the launch of its proprietary Outmax AI agent for TikTok. This integration extends Perion’s capabilities to one of the fastest-growing global advertising platforms, with nearly 1.6 billion users worldwide and rapidly expanding advertiser adoption as brands increasingly prioritize TikTok in their media strategies. TikTok’s advertising revenue is expected to exceed $50 billion by 20271. Perion’s Outmax AI agent is embedded within Perion’s AI-native infrastructure, designed to increase advertiser efficiency and performance. Fully integrated with TikTok, Outmax applies algorithmic intelligence beyond native platform defaults, enablin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom